These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 28578659)
1. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells. Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659 [TBL] [Abstract][Full Text] [Related]
2. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179 [TBL] [Abstract][Full Text] [Related]
3. In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors. Salamanca-Cardona L; Shah H; Poot AJ; Correa FM; Di Gialleonardo V; Lui H; Miloushev VZ; Granlund KL; Tee SS; Cross JR; Thompson CB; Keshari KR Cell Metab; 2017 Dec; 26(6):830-841.e3. PubMed ID: 29056515 [TBL] [Abstract][Full Text] [Related]
4. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816 [TBL] [Abstract][Full Text] [Related]
5. Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1α axis. Liu X; Yamaguchi K; Takane K; Zhu C; Hirata M; Hikiba Y; Maeda S; Furukawa Y; Ikenoue T PLoS One; 2021; 16(9):e0257090. PubMed ID: 34516556 [TBL] [Abstract][Full Text] [Related]
6. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925 [TBL] [Abstract][Full Text] [Related]
7. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339 [TBL] [Abstract][Full Text] [Related]
8. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602 [TBL] [Abstract][Full Text] [Related]
9. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Carbonneau M; M Gagné L; Lalonde ME; Germain MA; Motorina A; Guiot MC; Secco B; Vincent EE; Tumber A; Hulea L; Bergeman J; Oppermann U; Jones RG; Laplante M; Topisirovic I; Petrecca K; Huot MÉ; Mallette FA Nat Commun; 2016 Sep; 7():12700. PubMed ID: 27624942 [TBL] [Abstract][Full Text] [Related]
10. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells. Badur MG; Muthusamy T; Parker SJ; Ma S; McBrayer SK; Cordes T; Magana JH; Guan KL; Metallo CM Cell Rep; 2018 Oct; 25(4):1018-1026.e4. PubMed ID: 30355481 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Seltzer MJ; Bennett BD; Joshi AD; Gao P; Thomas AG; Ferraris DV; Tsukamoto T; Rojas CJ; Slusher BS; Rabinowitz JD; Dang CV; Riggins GJ Cancer Res; 2010 Nov; 70(22):8981-7. PubMed ID: 21045145 [TBL] [Abstract][Full Text] [Related]
13. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784 [TBL] [Abstract][Full Text] [Related]
14. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251 [TBL] [Abstract][Full Text] [Related]
15. TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells. Park J; Na HK; Shon HK; Son HY; Huh YM; Lee SW; Lee TG Biointerphases; 2018 Jan; 13(3):03B404. PubMed ID: 29382206 [TBL] [Abstract][Full Text] [Related]
16. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417 [TBL] [Abstract][Full Text] [Related]
17. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1). Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781 [TBL] [Abstract][Full Text] [Related]
18. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Batsios G; Viswanath P; Subramani E; Najac C; Gillespie AM; Santos RD; Molloy AR; Pieper RO; Ronen SM Sci Rep; 2019 Jul; 9(1):10521. PubMed ID: 31324855 [TBL] [Abstract][Full Text] [Related]
19. RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer. Zarei M; Lal S; Vaziri-Gohar A; O'Hayer K; Gunda V; Singh PK; Brody JR; Winter JM Mol Cancer Res; 2019 Feb; 17(2):508-520. PubMed ID: 30266754 [TBL] [Abstract][Full Text] [Related]